PetIQ (NASDAQ:PETQ) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Friday.
According to Zacks, “PetIQ, Inc. is a pet medication and wellness company. Its product consists of Rx Medications, OTC Medications and Supplies, Health and Wellness Products. The Company serves retail stores across the mass, club, grocery, pharmacy and e-commerce channels. PetIQ, Inc. is based in Eagle, United States. “
Separately, Jefferies Group raised their price target on shares of PetIQ from $25.00 to $26.00 and gave the company a “hold” rating in a report on Tuesday, November 7th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. PetIQ currently has an average rating of “Buy” and a consensus price target of $26.83.
Hedge funds have recently made changes to their positions in the business. American International Group Inc. bought a new position in PetIQ in the third quarter valued at approximately $131,000. Wells Fargo & Company MN bought a new position in PetIQ in the third quarter valued at approximately $204,000. California State Teachers Retirement System bought a new position in PetIQ in the third quarter valued at approximately $320,000. Schwab Charles Investment Management Inc. bought a new position in PetIQ in the third quarter valued at approximately $344,000. Finally, New York State Common Retirement Fund bought a new position in PetIQ in the third quarter valued at approximately $448,000. 56.49% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “PetIQ (PETQ) Downgraded by Zacks Investment Research” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/01/12/petiq-petq-downgraded-by-zacks-investment-research.html.
PetIQ, Inc is engaged in manufacturing and distributing pet medication and health and wellness products to the retail channel in the United States. The Company provides retail stores with third-party brands, including Frontline Plus, Heartgard Plus, PetAction Plus, Advecta II, Pet Lock Plus, Pet Lock Max, TruProfen and Heartshield.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about PetIQ? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PetIQ and related companies.